Progress in understanding cytomegalovirus drug resistance

被引:26
作者
Emery, VC [1 ]
机构
[1] UCL Royal Free & Univ Coll Med Sch, London NW3 2PF, England
关键词
ganciclovir; dynamics; cell culture; polymerase;
D O I
10.1016/S1386-6532(00)00165-7
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The molecular basis for cytomegalovirus drug resistance against currently used antivirals comprises two genetic loci. In the case of ganciclovir, mutations in both the UL97 protein kinase and UL64 DNA polymerase can lead to resistance, whereas for cidofovir and foscarnet only mutations in UL54 give rise to resistance. Clinically, resistance strains of cytomegalovirus appear after prolonged periods of antiviral therapy especially when treatment has been interrupted or is at sub-optimal doses. Knowledge of the replication dynamics of cytomegalovirus in vivo can be used to predict the virologic course of patients who develop resistance virus. Using such models, a good agreement between experimentally determined viral load and resistance patterns is observed. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:223 / 228
页数:6
相关论文
共 26 条
[1]   Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in renal transplant recipient [J].
Bienvenu, B ;
Thervet, E ;
Bedrossian, J ;
Scieux, C ;
Mazeron, MC ;
Thouvenot, D ;
Legendre, C .
TRANSPLANTATION, 2000, 69 (01) :182-184
[2]   Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease [J].
Boivin, G ;
Chou, SW ;
Quirk, MR ;
Erice, A ;
Jordan, MC .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (03) :523-528
[3]   Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis [J].
Bowen, EF ;
Emery, VC ;
Wilson, P ;
Johnson, MA ;
Davey, CC ;
Sabin, CA ;
Farmer, D ;
Griffiths, PD .
AIDS, 1998, 12 (06) :605-611
[4]  
Bowen EF, 1997, J VIROL METHODS, V68, P225
[5]  
CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125
[6]   FREQUENCY OF UL97 PHOSPHOTRANSFERASE MUTATIONS RELATED TO GANCICLOVIR RESISTANCE IN CLINICAL CYTOMEGALOVIRUS ISOLATES [J].
CHOU, SW ;
GUENTZEL, S ;
MICHELS, KR ;
MINER, RC ;
DREW, WL .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (01) :239-242
[7]   Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease [J].
Chou, SW ;
Marousek, G ;
Guentzel, S ;
Follansbee, SE ;
Poscher, ME ;
Lalezari, JP ;
Miner, RC ;
Drew, WL .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (03) :786-789
[8]   A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir [J].
Chou, SW ;
Meichsner, CL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :183-185
[9]   ANALYSIS OF THE UL97 PHOSPHOTRANSFERASE CODING SEQUENCE IN CLINICAL CYTOMEGALOVIRUS ISOLATES AND IDENTIFICATION OF MUTATIONS CONFERRING GANCICLOVIR RESISTANCE [J].
CHOU, SW ;
ERICE, A ;
JORDAN, MC ;
VERCELLOTTI, GM ;
MICHELS, KR ;
TALARICO, CL ;
STANAT, SC ;
BIRON, KK .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :576-583
[10]   THERAPEUTIC POTENTIAL OF HPMPC AS AN ANTIVIRAL DRUG [J].
DECLERCQ, E .
REVIEWS IN MEDICAL VIROLOGY, 1993, 3 (02) :85-96